|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Cardiology, University of
Vienna; the Ludwig Boltzmann Institute for Cardiovascular Research; the
Institute for Molecular Oncology, Vienna, Austria; and the Mount Sinai
School of Medicine, New York, NY.
Defined angiographically, no-reflow (NR) manifests as an acute
reduction in coronary flow in the absence of epicardial vessel obstruction. One candidate protein to cause coronary NR is tissue factor (TF), which is abundant in atherosclerotic plaque and a cofactor
for activated plasma coagulation factor VII. Scrapings from
atherosclerotic carotid arteries contained TF activity
(corresponding to 33.03 ± 13.00 pg/cm2 luminal
plaque surface). Active TF was sedimented, indicating that TF was
associated with membranes. Coronary blood was drawn from 6 patients
undergoing coronary interventions with the distal protection device
PercuSurge GuardWire (Traatek, Miami, FL). Fine particulate material
that was recovered from coronary blood showed TF activity
(corresponding to 91.1 ± 62.16 pg/mL authentic TF). To examine the
role of TF in acute coronary NR, blood was drawn via a catheter from
coronary vessels in 13 patients during NR and after restoration of
flow. Mean TF antigen levels were elevated during NR (194.3 ± 142.8
pg/mL) as compared with levels after flow restoration (73.27 ± 31.90
pg/mL; P = .02). To dissect the effects of particulate
material and purified TF on flow, selective intracoronary injection of
atherosclerotic material or purified relipidated TF was performed in a
porcine model. TF induced NR in the model, thus strengthening the
concept that TF is causal, not just a bystander to atherosclerotic
plaque material. The data suggest that active TF is released from
dissected coronary atherosclerotic plaque and is one of the factors
causing the NR phenomenon. Thus, blood-borne TF in the coronary
circulation is a major determinant of flow.
(Blood. 2002;99:2794-2800) The no-reflow (NR) phenomenon is defined as
profound reduction in antegrade coronary flow1 in the
absence of epicardial vessel obstruction.2,3 Despite a
0.6% to 2% incidence during percutaneous coronary
interventions2,4 and a 15% mortality,2 the
mechanisms underlying coronary NR are unclear. A common denominator of
various disorders leading to NR appears to be microvascular damage.5
One candidate protein to cause coronary NR is tissue factor (TF),
a 47-kd transmembrane glycoprotein and a member of the
cytokine-receptor superfamily. TF initiates blood coagulation by
binding activated coagulation factor VII (VIIa)6 with a
dissociation constant of around 10 pM.7 The
TF-VIIa complex proteolytically activates factors IX and X, triggering
the coagulation system.8 The activity of TF is lipid
dependent and is enhanced by a factor of 2000 to 3000 in the presence
of phosphatidylserine/phosphatidylcholine,9 allowing
almost immediate thrombus formation. Because TF-containing microparticles with procoagulant activity are abundant in
atherosclerotic plaque,10-13 spontaneous or mechanical
disruption of a coronary atherosclerotic plaque by angioplasty and/or
stenting could lead to release of active TF into the coronary blood.
First, we demonstrate that ex vivo plaque disruption by scraping leads
to release of membrane-bound active TF. Secondly, we show that in vivo
plaque disruption by angioplasty and/or stenting causes shedding of
active TF into the coronary blood. Third, we show that TF antigen
levels during coronary NR are elevated compared with the levels that
are measured in the same patients after restoration of flow. Finally,
we demonstrate that intracoronary injection of atherosclerotic plaque
material or purified TF causes microvascular thrombosis and NR in a
porcine model.
Harvest of carotid thromboendarterectomy specimens
Patient characteristics
The PercuSurge GuardWire (Traatek, Miami, FL) protection device was
used in 6 patients to prevent embolization of material into the
capillary bed (Table 1). In these patients, the location of the target
stenosis in venous grafts or in native vessel segments without side
branches allowed its use. The system served the study in that it
prevented losses of vessel wall-derived particles of any size into the
distal vascular bed. The distal over-the-wire occlusion balloon was
inflated shortly before the intervention and was held inflated during
the intervention with the use of the hypotube as angioplasty guidewire.
After removal of the intervention catheter, an aspiration catheter was
advanced into the coronary artery and 40 mL blood was drawn from the
coronary bed with the inflated distal balloon still in place (Figure
1A) and with a syringe used to serve as a
collection chamber. Then the distal balloon was deflated, and coronary
flow was restored. The aspirated material was passed over a small
filter unit (Falcon, 40-µm nylon) (Becton Dickinson, San Jose, CA).
Material trapped in the filter was resuspended in 1 mL HBS, and stored
at
In patients experiencing NR, blood was drawn through a no-sidehole guiding catheter from the target coronary artery (Figure 1B) after discarding 5-mL or 8-mL aspirates, respectively (with the use of a 6 or 7 French guiding catheter). Flow was classified according to the Thrombolysis In Myocardial Infarction (TIMI) study.1 Flow was defined as TIMI 0 when no antegrade flow was present; as TIMI 1 when penetration of contrast was present without perfusion, ie, without opacification of the entire coronary bed; as TIMI 2 when the rate of entry of contrast material into the distal vessel or its rate of clearance from the distal bed was perceptibly slower than its flow into or clearance from comparable areas not perfused by the target vessel; and as TIMI 3 when coronary flow was normal, ie when the rate of entry of contrast material into the distal vessel or its rate of clearance from the distal bed was as rapid as flow into or clearance from a normal uninvolved coronary vessel. Coronary blood samples from subjects undergoing coronary angiography for other indications, eg, valvular heart disease, or for a preoperative risk stratification and showing normal epicardial coronary arteries were collected as controls. Sodium citrate (at a final concentration of 0.129 M) was added to blood samples, and platelet-poor plasma (PPP) was prepared by centrifugation (1300g, 4°C, 10 minutes). To expose membrane-associated TF,14 PPP samples were also subjected to 4 freeze-thaw cycles prior to antigen measurements. All human studies were approved by the Ethics Committee of the University of Vienna, Austria. Differential centrifugation experiments Rinsing buffers from carotid scrapings were centrifuged at 23 000g (15 minutes, 20°C) (Universal 30RF centrifuge) (Hettich, Tuttlingen, Germany) and at 250 000g (60 minutes, 20°C) (Beckman L-80 ultracentrifuge SW 50.1-Rotor, Beckman Coulter, Fullerton, CA), corresponding to a particle size of 0.5 to 2 µm and 10 to 15 nm, respectively. TF activity measurements were performed in the starting materials, 23 000g and 250 000g pellets, and their respective supernatants.Reagents Human recombinant factor VIIa was a kind gift from Novo-Nordisk (Copenhagen, Denmark) and human recombinant TF (TF1-243) was a gift from Robert Kelley (Genentech, San Francisco, CA), to Yale Nemerson. The phospholipids used for relipidation of TF consisted of 40% 1,2-dioleoyl-sn-glycero-3-phosphatidylserine and 60% 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL). Factor X was purified from human plasma.14 Spectrozyme-Xa was from American Diagnostica (Greenwich, CT).Preparation of TF-phospholipid Human recombinant TF was incorporated into phospholipid vesicles at a phospholipid to protein molar ratio of 44 000:1 as previously described.15 Human TF has been shown to be a good initiator of clotting in pig plasma.16TF activity assay TF activity was measured by adding the sample to a solution containing 1 nM factor VIIa, 150 nM factor X, and 5 mM CaCl2. At intervals, samples were transferred to a microtiter plate in which each well contained 100 µL EDTA buffer (50 mM bicine, pH 8.5, 20 mM EDTA, 1 mg/mL BSA), which terminates production of factor Xa. Spectrozyme Xa (25 µL, 0.5 mM final concentration) (American Diagnostica) was added, and optical density was measured at 405 nm for 30 minutes by means of a kinetic enzyme-linked immunosorbent assay (ELISA) plate reader (BTK Microquant, Software KC4) (Biotek, Winooski, VT) at 35°C. A standard curve was generated with the use of relipidated recombinant human TF.TF antigen assay Imubind Tissue Factor ELISA Kit No. 845 (American Diagnostica) was used according to the manufacturer's instructions.Immunoelectron microscopy The PercuSurge specimens were fixed in 3% freshly depolymerized paraformaldehyde in phosphate-buffered saline (PBS) (pH 7.4) for 1 hour at 4°C, rinsed in PBS, and dehydrated in increasing concentrations of ethanol (30%, 50%, 70%, 95%, and 100%, 30 to 60 minutes each). The resin infiltration was achieved by increasing concentrations of HM20 resin (Lowicryl, Chemische Werke Lowi, Waldkraiburg, Germany) at 35°C. The resin was cured under UV light for 48 hours at
35°C and polymerized for 48 hours without UV light at room
temperature. For immunostaining, 100-nm thin sections were mounted on
grids and incubated in PBS with 3% BSA and 0.05% Tween-20, pH 7.4 (PBS-ST) to block unspecific binding sites. The primary antibody was
monoclonal anti-TF (1:40, 2.5 hours at room temperature17)
in PBS-ST, followed by 3 rinses in PBS and incubation with protein
A-14-nm colloidal gold for 1 hour. The sections were rinsed in PBS and
distilled water 3 times each and contrasted in aqueous 2%
uranylacetate for 8 minutes and lead acetate for 2.5 minutes before
examination in a Zeiss transmission electron microscope (Zeiss,
Munich-Hallbergmoos, Germany).
Animal protocol Ten domestic pigs (33 ± 6 kg) of both genders fed on a standard natural diet were studied. The animals were anesthetized with intravascular ketamine (30 mg/kg), acepromazin (12 mg/kg), thiopental (5 mg/kg), and robinul (0.025 mg/kg) and a continuous infusion of fentanyl (0.08 mg/kg). Following endotracheal intubation, the pigs were mechanically ventilated with a mixture of 20% pure oxygen and 80% room air. Arteriotomy of the carotid artery and insertion of a 7F sheath were performed under sterile conditions. Electrocardiogram, arterial blood pressure, and temperature were recorded throughout the procedure. After administration of 2000 IU heparin, the RCA was cannulated, and a 0.014-inch Doppler ultrasound guide wire (FloWire) (Cardiometrics, Mountain View, CA) was introduced to the midpart of the artery. The average peak flow velocity (APV) was assessed at baseline and during maximal hyperemia after intracoronary bolus injection of 18 µg adenosine (centimeters per second, peak APV), and the coronary flow reserve was calculated as a ratio of peak APV and baseline APV. We injected 1 mL carotid scraping material containing 33 pg/mL TF activity or 250 µL of 39 nmol relipidated human TF, respectively, as a bolus through a deeply intubated 7F Judkins standard RCA guiding catheter. Angiograms were performed before and during the first 30 minutes after injection. The pigs were killed by saturated potassium chloride. The protocol was approved by the Animal Subjects Committee of the University of Vienna.Immunohistochemical analysis Immediately after the pigs were killed, multiple transmural biopsies from the RCA-dependent left ventricular posterior wall and from the anterior wall myocardium were obtained. Tissues and PercuSurge material were fixed in 7.5% buffered formalin and were embedded in paraffin, and serial 3-µm sections were stained as described18 by means of mouse monoclonal antibodies against fibrin (1:50) (Biodesign International, Saco, ME) and TF (1:100, human TF1).17 In addition, for immunostaining of PercuSurge samples, anti-CD15 (1:25) (DAKO, Glostrup, Denmark) and anti-CD61 (1:25) (DAKO) mouse monoclonal antibodies were used.Computer-assisted quantitative histological evaluation Following immunohistochemistry, sections from all specimens were scanned in their full size by means of the AxioCam color digital camera (Zeiss). Computer-based planimetry of the area of microvascular thrombosis was performed by means of the AxioVision 2.05 software package (Zeiss). Fibrin stains and modified trichrome stains served to identify thrombus. Two observers who were blinded to the origin of the specimens independently analyzed 4 different areas of each section, and 4 sections per specimen.Statistical analysis Results are expressed as means ± SD. Comparisons were made with the Mann-Whitney U test and the paired t test. P < .05 was considered significant.
Mechanical plaque disruption leads to shedding of membrane particles with procoagulant activity To simulate intervention-related mechanical plaque damage ex vivo, 6 carotid thromboendarterectomy specimens were scraped, and TF activity was determined in the rinsing buffers. Mean procoagulant activity corresponded to 33.03 ± 13.00 pg/mL authentic TF per square centimeter scraped carotid intimal flap area. The TF activity in fractions obtained after differential centrifugation of carotid atherosclerotic plaque scrapings were as follows: 180.16 ± 95.55 for the 23 000g pellet; 5.63 ± 2.32 for the corresponding supernatant; 98.23 ± 34.60 for the 250 000g pellet; and 0 for the corresponding supernatant. Thus, complete removal of active TF from the rinsing buffers was accomplished by ultracentrifugation at 250 000g, indicating that TF activity was membrane associated. P = .03 for the differences between the starting material and the respective pellets. Part of the plaque material was used for injection into porcine coronary arteries.Coronary angioplasty and stenting are associated with shedding of procoagulant activity from the plaque into the coronary blood To confirm that intervention-related disruption of a coronary atherosclerotic plaque in vivo leads to release of active TF into the coronary blood, blood samples were harvested during angioplasty with a distal protection device, PercuSurge, in 6 patients (Table 1). Fine particulate material was trapped in the filter and was recovered in rinsing buffer. By light microscopy, the filter material contained mainly leukocytes, platelets, and vast amounts of amorphous material with cholesterol crystals. Immunohistochemically, TF colocalized with leukocytes, platelets, and fibrin (Figure 2). Manual cell counts showed that only approximately 2% of CD15+ cells demonstrated immunoreactivity with anti-TF antibody. By immunoelectron microscopy, TF was identified within platelets (insert, Figure 2C) and found attached to fibrin (insert, Figure 2D).
The rinsing solutions contained procoagulant activity corresponding to 91.10 ± 62.16 pg per milliliter of authentic TF (Table 1). In addition, plasma TF was measured in the blood column proximal to the PercuSurge occlusion balloon (Figure 1A) and after release of the occlusion balloon with reflow (R) in the distal part of the vessel (Table 1). TF antigen was significantly lower under conditions of R (99.62 ± 39.16 pg/mL versus 48.78 ± 23.80 pg/mL, P = .028). Coronary TF antigen is elevated during NR To investigate acute coronary NR, blood was drawn from coronary vessels in 13 patients during percutaneous interventions. The circumstances of NR are depicted in Table 2. TF antigen levels were elevated during NR (194.3 ± 142.8 pg/mL) as compared with the TF levels in plasmas from control subjects (100.3 ± 60.7 pg/mL, P = .0333). TF antigen levels after freeze thawing of NR samples increased, while TF levels in plasmas from control subjects were unchanged after freeze thawing (Figure 3). TF was also elevated compared with samples obtained after flow restoration (73.27 ± 31.90 pg/mL, n = 7, P = .02). These values were not different from controls (P = .28). Flow restoration (TIMI 3) was achieved by sealing of culprit lesions with stents and by intracoronary pharmacological treatment (see "Patients, materials, and methods") in patients no. 1 through 7. A dilution phenomenon through radiographic contrast did not occur because hematocrit values in the 2 samples were similar (40% ± 2% versus 39% ± 3%, NR/R).
Injection of TF induces NR in a porcine model To demonstrate that TF is causal to NR and to exclude that TF accumulation in coronary blood is secondary to stasis, an animal model was established. Injection of atherosclerotic plaque material or TF into the porcine RCA compromised flow in 9 of 10 animals within 30 seconds. For quantification of myocardial blood flow, coronary flow reserve determinations were used. Adenosine-dependent coronary flow reserve after injection of atherosclerotic plaque material/TF immediately dropped from 2.0 ± 1 to 0.9 ± 0.6 in 9 pigs, with a marked decrease of baseline flow immediately after the injection. NR/slow-flow spontaneously resolved in 5 pigs over the following 20 minutes, while it persisted in the remaining animals. Two NR pigs spontaneously went into ventricular fibrillation. Histologically, positive TF staining (Figure 4A,B) was identified in the microvasculature distal to the RCA that was filled with fibrin thrombi (Figure 4C,D). In plaque-injected animals, embolic obstruction was observed with surrounding thrombus (Figure 4A,C,E). No TF was detected on luminal endothelial cells.
There was no difference in the area of thrombosis in plaque-injected animals (4.0% ± 2.5% of the total field) versus TF-injected animals (3.8% ± 2.0% of the total field, P > .05) No fibrin deposition was detected in any noninjected myocardial vessel (Figure 4G,H). No correlation was observed between thrombus area and TIMI flow grade or coronary flow reserve.
Our data provide important new insights into the mechanisms
underlying NR inasmuch as injection of human TF-containing
atherosclerotic plaque material or purified relipidated recombinant
human TF into porcine RCAs led to flow impairment. Thus, we have
established an experimental model that mimics human NR. Histological
analysis revealed microthrombi in all animals, with 9 of 10 demonstrating TIMI flow of 2 or less (Table
3). The most extensive area of microvascular fibrin thrombi was observed in animals with TIMI 0 flow.
We speculate that NR occurs when the capacity of the regional coronary
microvascular bed is exhausted; ie, when all vessels in a given domain
are obstructed. Such obstruction may occur spontaneously, through
shedding of particulate material and TF from ruptured plaque during
acute coronary syndromes, or iatrogenically, from PTCA and stent
implantation. However, other factors that are as yet unknown may
exacerbate the flow disturbances.
Contribution of the coagulation system to the pathogenesis of coronary NR is a novel observation. Recent experimental work of Giesen et al19 has lent support to the concept that blood-borne TF is a powerful thrombogenic species. In the present work, we captured active TF in a distal protection device from patients undergoing coronary revascularization. Other studies found that 20- to 60-nm vesicles were recovered by scraping pig aorta,20 demonstrating that the vessel wall itself may be a source of circulating TF. TF captured in the PercuSurge filter colocalized with leukocytes (Figure 3). Because circulating white blood cells upregulate TF only 24 to 48 hours after the percutaneous intervention,21 these TF-positive cells most likely originate from ruptured plaque, which is in line with previous findings.10 In addition, TF was found associated with platelets and fibrin (Figure 2C,D), which is in accord with recently published data.22 TF uptake by platelets and binding to fibrin may account for our observation that after restoration of flow, TF antigen returns to normal in plasma. We found an increase of TF antigen after freeze thawing of PPP from NR (Figure 3), indicating some TF is in a protected state. It is known that TF incorporates into vesicles in such a way that half the molecules are facing outward and are therefore available to initiate coagulation while the other half are sequestered within the vesicle.15 Freeze thawing has been shown to reorient TF in such a way that half the sequestered molecules become available for coagulation. We have no information regarding the symmetry of the particles released following angioplasty, but the increase in immunologically detectable TF after freeze thawing suggests that some of the TF is sequestered. These molecules may, however, become available during thrombogenesis. There is currently no information regarding this hypothesis although it is being investigated in our laboratories. It is known that TF antigen is elevated23 and that TF-positive microparticles have been captured on annexin V-coated plates from the blood of patients with unstable coronary artery disease.24 However, Mallat et al24 investigated systemic venous blood samples up to 8 days following an acute ischemic episode. It is therefore possible that secondary immunological or inflammatory effects resulted in TF release from other sites. In contrast, the present study focuses on a single atherosclerotic target lesion or vessel as the culprit for the clinical syndrome. Former work has emphasized the roles of microvascular spasm5 and inflammation25 in the development of NR. The lack of a significant inflammatory response in our animal experiments is due to the short observation period. TF initiates the coagulation cascade within seconds, resulting in thrombin generation and fibrin deposition. Thrombin is able to induce vasospasm26,27 by activation of protease-activated receptors.28,29 In fact, inhibition of thrombin with hirudin was shown to limit infarct size in a rabbit coronary ligation model.30 Microvascular patency and consequently myocardial perfusion are predictors of mortality after thrombolytic therapy31 and after stent implantation in acute myocardial infarction.32 The observation that administration of antibody directed against glycoprotein IIb/IIIa had no effect on peri-interventional slow-flow in a meta-analysis of the EPIC and EPILOG studies33 lends support to the concept that small tears liberating the lipid core of atherosclerotic plaque allow active TF to enter the coronary bed and cause coronary flow deceleration, culminating in NR. In this regard, it is noteworthy that unstable plaques contain more TF activity than stable plaques.12,13 In the present study, 11 of 13 patients experiencing NR (Table 2) were unstable prior to the occurrence of NR. Active TF shed from dissected atherosclerotic plaque is associated with microvascular thrombosis and macrovascular slow-flow/NR. The concept that TF is a major player in the pathogenesis of NR is also supported by previous studies in a baboon model of middle cerebral artery occlusion, where NR was reversed with the administration of a TF antibody.34 In more recent experimental work, recombinant human, active site-blocked factor VIIa reduced infarct size and NR in rabbits.35,36 These observations support the view that clinical studies should be undertaken to investigate whether anti-TF agents are useful in the treatment of peri-interventional slow-flow and NR.
The authors are grateful to Dr Marin Guentschev for expert technical advice. The study would not have been possible without the support of the interventional coronary catheter laboratory staff and animal laboratory personnel of the University of Vienna.
Submitted July 13, 2001; accepted November 28, 2001.
Supported in part by the Austrian fellowship grants FWF P13834-MED and Nationalbank Jubiläumsfonds No. 7710 (I.M.L.); Hans und Blanca Moser-Stiftung (D.B.); and National Institutes of Health grants HL 29019 and HL 54469 (Y.N.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Irene M. Lang, Dept of Internal Medicine II, Division of Cardiology, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria; e-mail: irene.lang{at}univie.ac.at.
1. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932-936[Medline] [Order article via Infotrieve]. 2. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995;75:778-782[CrossRef][Medline] [Order article via Infotrieve].
3.
Eeckhout E, Kern MJ.
The coronary no-reflow phenomenon: a review of mechanisms and therapies.
Eur Heart J.
2001;22:729-739
4.
Piana RN, Paik GY, Moscucci M, et al.
Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.
Circulation.
1994;89:2514-2518 5. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508. 6. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991;66:67-79[Medline] [Order article via Infotrieve]. 7. Waxman E, Ross JB, Laue TM, et al. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry. 1992;31:3998-4003[CrossRef][Medline] [Order article via Infotrieve]. 8. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coagul Fibrinolysis. 1993;4:281-292[Medline] [Order article via Infotrieve]. 9. Nemerson Y. Tissue factor: then and now. Thromb Haemost. 1995;74:180-184[Medline] [Order article via Infotrieve].
10.
Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A.
Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity.
Circulation.
1999;99:348-353 11. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest. 1996;75:451-461[Medline] [Order article via Infotrieve].
12.
Marmur JD, Thiruvikraman SV, Fyfe BS, et al.
Identification of active tissue factor in human coronary atheroma.
Circulation.
1996;94:1226-1232 13. Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis. 1999;144:273-283[CrossRef][Medline] [Order article via Infotrieve]. 14. Miletich J, Broze GJ, Majerus PW. Methods Enzymol. 1981;80:221. 15. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry. 1986;25:4007-4020[CrossRef][Medline] [Order article via Infotrieve]. 16. Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis. 1984;14:440-444[Medline] [Order article via Infotrieve].
17.
Carson SD, Ross SE, Bach R, Guha A.
An inhibitory monoclonal antibody against human tissue factor.
Blood.
1987;70:490-493
18.
Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR.
Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli.
Circulation.
1994;89:2715-2721
19.
Giesen PL, Rauch U, Bohrmann B, et al.
Blood-borne tissue factor: another view of thrombosis.
Proc Natl Acad Sci U S A.
1999;96:2311-2315 20. Taubman MB, Giesen PL, Schecter AD, Nemerson Y. Regulation of the procoagulant response to arterial injury. Thromb Haemost. 1999;82:801-805[Medline] [Order article via Infotrieve].
21.
Ott I, Andrassy M, Zieglgansberger D, Geith S, Schomig A, Neumann FJ.
Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1.
Blood.
2001;97:3721-3726
22.
Rauch U, Bonderman D, Bohrmann B, et al.
Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.
Blood.
2000;96:170-175
23.
Soejima H, Ogawa H, Yasue H, et al.
Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina.
Circulation.
1999;99:2908-2913
24.
Mallat Z, Benamer H, Hugel B, et al.
Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.
Circulation.
2000;101:841-843
25.
Dorge H, Neumann T, Behrends M, et al.
Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation.
Am J Physiol Heart Circ Physiol.
2000;279:H2587-H2592 26. Jerius H, Beall A, Woodrum D, Epstein A, Brophy C. Thrombin-induced vasospasm: cellular signaling mechanisms. Surgery. 1998;123:46-50[Medline] [Order article via Infotrieve].
27.
Ku DD.
Coronary vascular reactivity after acute myocardial ischemia.
Science.
1982;218:576-578 28. Saifeddine M, Roy SS, Al-Ani B, Triggle CR, Hollenberg MD. Endothelium-dependent contractile actions of proteinase-activated receptor-2-activating peptides in human umbilical vein: release of a contracting factor via a novel receptor. Br J Pharmacol. 1998;125:1445-1454[CrossRef][Medline] [Order article via Infotrieve].
29.
Carlino M, DeGregorio J, Di Mario C, et al.
Prevention of distal embolization during saphenous vein graft lesion angioplasty: experience with a new temporary occlusion and aspiration system.
Circulation.
1999;99:3221-3223
30.
Erlich JH, Boyle EM, Labriola J, et al.
Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.
Am J Pathol.
2000;157:1849-1862
31.
Gibson CM, Cannon CP, Murphy SA, et al.
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.
Circulation.
2000;101:125-130
32.
Nunn CM, O'Neill WW, Rothbaum D, et al.
Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial.
J Am Coll Cardiol.
1999;33:640-646 33. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts: EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Am J Cardiol. 1997;80:985-988[CrossRef][Medline] [Order article via Infotrieve].
34.
Thomas WS, Mori E, Copeland BR, Yu JQ, Morrissey JH, del Zoppo GJ.
Tissue factor contributes to microvascular defects after focal cerebral ischemia [discussion appears in Stroke. 1993;24:847].
Stroke.
1993;24:847-853
35.
Golino P, Ragni M, Cirillo P, et al.
Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits.
Am J Physiol Heart Circ Physiol.
2000;278:H1507-H1516 36. Golino P, Ragni M, Cirillo P, et al. Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S149-S158.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Mayr, D. Grainger, U. Mayr, A. S. Leroyer, G. Leseche, A. Sidibe, O. Herbin, X. Yin, A. Gomes, B. Madhu, et al. Proteomics, Metabolomics, and Immunomics on Microparticles Derived From Human Atherosclerotic Plaques Circ Cardiovasc Genet, August 1, 2009; 2(4): 379 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tanaka, T. Imanishi, H. Kitabata, T. Kubo, S. Takarada, T. Tanimoto, A. Kuroi, H. Tsujioka, H. Ikejima, K. Komukai, et al. Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study Eur. Heart J., June 1, 2009; 30(11): 1348 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Libby Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S352 - S357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Leroyer, P.-E. Rautou, J.-S. Silvestre, Y. Castier, G. Leseche, C. Devue, M. Duriez, R. P. Brandes, E. Lutgens, A. Tedgui, et al. CD40 Ligand+ Microparticles From Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis: A Potential Mechanism for Intraplaque Neovascularization J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1302 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M. Okorie, W. S. Denney, M. S. Chatterjee, K. B. Neeves, and S. L. Diamond Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow Blood, April 1, 2008; 111(7): 3507 - 3513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text]
|
|
|
|
 |
|
 M. Canault, A. S. Leroyer, F. Peiretti, G. Leseche, A. Tedgui, B. Bonardo, M.-C. Alessi, C. M. Boulanger, and G. Nalbone Microparticles of Human Atherosclerotic Plaques Enhance the Shedding of the Tumor Necrosis Factor-{alpha} Converting Enzyme/ADAM17 Substrates, Tumor Necrosis Factor and Tumor Necrosis Factor Receptor-1 Am. J. Pathol., November 1, 2007; 171(5): 1713 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, S. Mangan, and P. Clancy Effects of Peroxisome Proliferator-Activated Receptor Ligands in Modulating Tissue Factor and Tissue Factor Pathway Inhibitor in Acutely Symptomatic Carotid Atheromas Stroke, May 1, 2007; 38(5): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lerman, D. R. Holmes, J. Herrmann, and B. J. Gersh Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? Eur. Heart J., April 1, 2007; 28(7): 788 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Leroyer, H. Isobe, G. Leseche, Y. Castier, M. Wassef, Z. Mallat, B. R. Binder, A. Tedgui, and C. M. Boulanger Cellular Origins and Thrombogenic Activity of Microparticles Isolated From Human Atherosclerotic Plaques J. Am. Coll. Cardiol., February 20, 2007; 49(7): 772 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Morel, F. Toti, B. Hugel, B. Bakouboula, L. Camoin-Jau, F. Dignat-George, and J.-M. Freyssinet Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2594 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, S. A. Murphy, C. H. McCabe, N. Mackman, H. C. Wong, E. M. Antman, and on behalf of the PROXIMATE-TIMI 27 Investigators Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial Eur. Heart J., April 1, 2005; 26(7): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamashita, E. Furukoji, K. Marutsuka, K. Hatakeyama, H. Yamamoto, S. Tamura, Y. Ikeda, A. Sumiyoshi, and Y. Asada Increased Vascular Wall Thrombogenicity Combined With Reduced Blood Flow Promotes Occlusive Thrombus Formation in Rabbit Femoral Artery Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2420 - 2424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mackman Role of Tissue Factor in Hemostasis, Thrombosis, and Vascular Development Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1015 - 1022. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) and from
controls with TIMI 3 flow in angiographically normal coronary
arteries (n = 13, 
).
